PT  - JOURNAL ARTICLE
AU  - Rendo, Veronica
AU  - Lee, Eudocia Q.
AU  - Bossi, Connor
AU  - Khuu, Nicholas
AU  - Rudek, Michelle A.
AU  - Pal, Sangita
AU  - Reynolds, Abigail R. N.
AU  - Fassinou, Auriole C.R.
AU  - Ayoub, Georges
AU  - Lapinskas, Emily
AU  - Pisano, William
AU  - Jeang, John
AU  - Stopka, Sylwia A.
AU  - Regan, Michael S.
AU  - Spetz, Johan
AU  - Desai, Arati
AU  - Lieberman, Frank
AU  - Fisher, Joy D.
AU  - Pelton, Kristine
AU  - Huang, Raymond Y.
AU  - Nabors, Louis B.
AU  - Holdhoff, Matthias
AU  - Danda, Neeraja
AU  - Strowd, Roy
AU  - Desideri, Serena
AU  - Walbert, Tobias
AU  - Ye, Xiaobu
AU  - Agar, Nathalie Y. R.
AU  - Grossman, Stuart A.
AU  - Alexander, Brian M.
AU  - Wen, Patrick Y.
AU  - Ligon, Keith L.
AU  - Beroukhim, Rameen
TI  - Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma
AID  - 10.1101/2024.08.12.24311893
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.12.24311893
4099  - http://medrxiv.org/content/early/2024/08/14/2024.08.12.24311893.short
4100  - http://medrxiv.org/content/early/2024/08/14/2024.08.12.24311893.full
AB  - We investigated the effectiveness of navtemadlin (KRT-232) in treating recurrent glioblastoma. A surgical window-of-opportunity trial (NCT03107780) was conducted on 21 patients to determine achievable drug concentrations within tumor tissue and examine mechanisms of response and resistance. Both 120 mg and 240 mg daily dosing achieved a pharmacodynamic impact. Sequencing of three recurrent tumors revealed an absence of TP53-inactivating mutations, indicating alternative mechanisms of resistance. In patient-derived GBM models, the lower range of clinically achieved navtemadlin concentrations induced partial tumor cell death as monotherapy. However, combining navtemadlin with temozolomide increased apoptotic rates while sparing normal bone marrow cells in vitro, which in return underwent reversible growth arrest. These results indicate that clinically achievable doses of navtemadlin generate significant pharmacodynamic effects and suggest that combined treatment with standard-of-care DNA damaging chemotherapy is a route to durable survival benefits.Statement of significance Tissue sampling during this clinical trial allowed us to assess mechanisms of response and resistance associated with navtemadlin treatment in recurrent GBM. We report that clinically achievable doses of navtemadlin induce pharmacodynamic effects in tumor tissue, and suggest combinations with standard-of-care chemotherapy for durable clinical benefit.Competing Interest StatementN.Y.R.A is key opinion leader for Bruker Daltonics, and receives support from Thermo Finnegan and EMD Serono. The other authors declare no competing financial interests.Clinical TrialNCT03107780Funding StatementThis study was sponsored by the Adult Brain Tumor Consortium (ABTC) NIH/NCI UM1 CA137443, NIH grants U54-CA210180 (NYRA), P41-EB028741 (NYRA), U19CA264504, R01CA262462 (RB and KL), R0188228 (RB and KL), and Capital Award from the Massachusetts Life Sciences Center. The project described was also supported by the Analytical Pharmacology Core of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins [NIH grants P30CA006973 and UL1TR003098, and the Shared Instrument Grant S10RR026824], the Gray Matters Brain Cancer Research Foundation, The Brain Tumour Charity, and the Swedish Research Council. The grant number UL1TR003098 is from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCATS or NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Dana-Farber Cancer Institute and Brigham and Women's Hospital gave Eudocia Q. Lee ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors